Searched for
ABSORICA
Stock Analysis: One-off blues no reason to give up on Sun PharmaAnalysts have cut their price targets marginally following the hit on bottom line.- Buy Sun Pharma, target price Rs 528: ICICI SecuritiesThe brokerage expects US revenue growth to remain low in the near term with gradual ramp-up in the specialty portfolio offset by likely gen...
- Reduce Sun Pharma, target Rs 450: IIFLReduce Sun Pharmaceutical Industries Ltd. at a price target of Rs 450.0 .
- Reduce Sun Pharma, target Rs 447: Prabhudas LilladherReduce Sun Pharmaceutical Industries Ltd. at a price target of Rs 447.
- Cipher, Ranbaxy settle patent litigation with ActavisCipher Pharma Inc, along with partners Ranbaxy - a Sun Pharma firm - and Galephar Pharmaceutical Research, has entered into a patent litiga...
- Ranbaxy launches acne treatment capsules in the US marketRanbaxy Laboratories Inc has announced the launch of Absorica capsules in the strengths of 25 mg and 35 mg in the US market.
- Ranbaxy Q1 net loss narrows to Rs 185.92 croreRanbaxy's net loss in the April-June quarter was at Rs 186 crore ($30.94 million), compared with a loss of Rs 524 crore a year earlier.
- Ranbaxy inks pact with Cipher to sell acne drug in BrazilRanbaxy has inked a licensing pact with Cipher Pharmaceuticals Inc to exclusively market its isotretinoin capsules, used to treat acne, in ...
- Ranbaxy net loss at Rs 73.6 crore in Jan-Mar quarterRanbaxy's net sales during Q4, 2013-14 grew marginally by 1.03 per cent to Rs 2,436.1 crore, as against Rs 2,411.1 crore in the year-ago pe...
- Ranbaxy March quarter performance disappointing, all eyes on clearance of merger with Sun PharmaFlat growth in revenues, net loss of Rs 73.6 crore against a profit of Rs 125.7 crore in the March quarter of previous year led to a dismal...
- Will Ranbaxy Labs be the next turnaround story?Hopes of settlement with US Food and Drug Administration, a strong product pipeline & a discounted P/E make Ranbaxy Laboratories attractive.
- Ranbaxy sues Actavis in US; stock rallies over 3%At 06:35 pm; Ranbaxy pared some of the morning gains and was trading 1.9% higher at Rs 411.05.
- Ranbaxy sues Actavis in US to prevent sale of acne genericAbsorica helped Ranbaxy shore up its sales in the US market in the September quarter. The drug commands 19% market share in the US.
- Watson Laboratories send patent challenge notice to Ranbaxy for acne drugRanbaxy Laboratories' US arm has received a notice from Watson Laboratories, challenging the patent of acne treatment drug Absorica.
- Ranbaxy shares fall over 5% as trouble brews in US marketThe stock plunged over 5% on reports that the US-based Ohm Laboratories-the company's facility in US, is under the surveillance of FDA.
- Ranbaxy gains 34%: Five reasons why the stock was on a highThe surge comes on a day when Malaysia allotted its JV the site for a manufacturing unit, and a day after the firm reported Q2 earnings.
- Brokerages lower Ranbaxy EPS estimates post Q1 resultsThe pharmaceutical major’s Q1 net profit fell 90 per cent to Rs 126 crore as against a net profit of Rs 1,246 crore YoY.
- Ranbaxy launches anti-acne drug in the US marketAccording to an analyst, the launch of Absorica would greatly benefit Ranbaxy as there are only 2-3 players currently selling the product i...
- Ranbaxy to relaunch bessling brandRanbaxy Laboratories has received US drug regulator's approval to relaunch one of its best selling brand in the US after being banned for n...
- Ranbaxy receives USFDA approval for anti acne drug AbsoricaRanbaxy laboratories has received an approval for an anti acne drug Absorica developed by US firm Cipher, the company said in a release to ...
Load More
